Fibroblastic tumors of intermediate malignancy in childhood

References

• WHO Classification of Tumours. Pathology and Genetics. Tumours of Soft Tissue and Bone. Fletcher CDM, Unni KK, Mertens F (Eds). IARC Press, Lyon, France (2002).
   Google Scholar
• Coffin C, Boccon-Gibod L. Fibroblastic-myofibroblastic proliferations of childhood and adolescents. Ann. Pathol. 24(6), 605–620 (2004).
   PubMed Web of Science ®Google Scholar
• Allen PW. The fibromatoses: a clinicopathologic classification based on 140 cases. Am. J. Surg. Pathol. 1(3), 255–270 (1977).
   PubMed Web of Science ®Google Scholar
• Levine E, Fréneaux P, Schleiermacher G et al. Risk-adapted therapy for infantile myofibromatosis in children. Pediatr. Blood Cancer 59(1), 115–120 (2012).
   PubMed Web of Science ®Google Scholar
• Fetsch JF, Miettinen M, Laskin WB, Michal M, Enzinger FM. A clinicopathologic study of 45 pediatric soft tissue tumors with an admixture of adipose tissue and fibroblastic elements, and a proposal for classification as lipofibromatosis. Am. J. Surg. Pathol. 24(11), 1491–1500 (2000).
   PubMed Web of Science ®Google Scholar
• Fetsch JF, Laskin WB, Miettinen M. Palmar-plantar fibromatosis in children and preadolescents: a clinicopathologic study of 56 cases with newly recognized demographics and extended follow-up information. Am. J. Surg. Pathol. 29(8), 1095–1105 (2005).
   PubMed Web of Science ®Google Scholar
• Spiegel DA, Dormans JP, Meyer JS et al. Aggressive fibromatosis from infancy to adolescence. J. Pediatr. Orthop. 19(6), 776–784 (1999).
   PubMed Web of Science ®Google Scholar
• Faulkner LB, Hajdu SI, Kher U et al. Pediatric desmoid tumor: retrospective analysis of 63 cases. J. Clin. Oncol. 13(11), 2813–2818 (1995).
   PubMed Web of Science ®Google Scholar
• Godzin´ski W, Sulka M, Ra˛pała E, Bien´ M, Kurylak CA et al. Aggressive fibromatosis: a challenge for pediatric oncology surgery. Pediatr. Blood Cancer 41, 278 (2003).
   Google Scholar
• Goldblum J, Fletcher JA. Desmoid-type fibromatosis. In: WHO Classification of Tumors: Pathology and Genetics of Tumors of Soft Tissue and Bone. Fletcher CDM, Unni KK, Mertens F (Eds). International Agency for Research on Cancer Press, Lyon, France, 83–84 (2002).
   Google Scholar
• Posner MC, Shiu MH, Newsome JL, Hajdu SI, Gaynor JJ, Brennan MF. The desmoid tumor. Not a benign disease. Arch. Surg. 124(2), 191–196 (1989).
   PubMedGoogle Scholar
• Shields CJ, Winter DC, Kirwan WO, Redmond HP. Desmoid tumours. Eur. J. Surg. Oncol. 27(8), 701–706 (2001).
   PubMed Web of Science ®Google Scholar
• Bertario L, Russo A, Sala P et al.; Hereditary Colorectal Tumor Registry. Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J. Clin. Oncol. 21(9), 1698–1707 (2003).
   PubMed Web of Science ®Google Scholar
• Lefevre JH, Parc Y, Kernéis S et al. Risk factors for development of desmoid tumours in familial adenomatous polyposis. Br. J. Surg. 95(9), 1136–1139 (2008).
   PubMed Web of Science ®Google Scholar
• Soravia C, Berk T, McLeod RS, Cohen Z. Desmoid disease in patients with familial adenomatous polyposis. Dis. Colon Rectum 43(3), 363–369 (2000).
   PubMed Web of Science ®Google Scholar
• Li C, Bapat B, Alman BA. Adenomatous polyposis coli gene mutation alters proliferation through its beta-catenin-regulatory function in aggressive fibromatosis (desmoid tumor). Am. J. Pathol. 153(3), 709–714 (1998).
   PubMed Web of Science ®Google Scholar
• Meazza C, Bisogno G, Gronchi A et al. Aggressive fibromatosis in children and adolescents: the Italian experience. Cancer 116(1), 233–240 (2010).
   PubMed Web of Science ®Google Scholar
• Meazza C, Alaggio R, Ferrari A. Aggressive fibromatosis in children: a changing approach. Minerva Pediatr. 63(4), 305–318 (2011).
   PubMed Web of Science ®Google Scholar
• Lewis JJ, Boland PJ, Leung DH, Woodruff JM, Brennan MF. The enigma of desmoid tumors. Ann. Surg. 229(6), 866–872; discussion 872 (1999).
   PubMed Web of Science ®Google Scholar
• Alman BA, Li C, Pajerski ME, Diaz-Cano S, Wolfe HJ. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am. J. Pathol. 151(2), 329–334 (1997).
   PubMed Web of Science ®Google Scholar
• Tejpar S, Nollet F, Li C et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 18(47), 6615–6620 (1999).
   PubMed Web of Science ®Google Scholar
• Salas S, Chibon F, Noguchi T et al. Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors. Genes. Chromosomes Cancer 49(6), 560–568 (2010).
   PubMed Web of Science ®Google Scholar
• Colombo C, Bolshakov S, Hajibashi S et al. ‘Difficult to diagnose’ desmoid tumours: a potential role for CTNNB1 mutational analysis. Histopathology 59(2), 336–340 (2011).
   PubMed Web of Science ®Google Scholar
• Wang WL, Nero C, Pappo A, Lev D, Lazar AJ, López-Terrada D. CTNNB1 genotyping and APC screening in pediatric desmoid tumors: a proposed algorithm. Pediatr. Dev. Pathol. 15(5), 361–367 (2012).
   PubMed Web of Science ®Google Scholar
• Dômont J, Salas S, Lacroix L et al. High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. Br. J. Cancer 102(6), 1032–1036 (2010).
   PubMed Web of Science ®Google Scholar
• Lazar AJ, Tuvin D, Hajibashi S et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am. J. Pathol. 173(5), 1518–1527 (2008).
   PubMed Web of Science ®Google Scholar
• Signoroni S, Frattini M, Negri T et al. Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis. Clin. Cancer Res. 13(17), 5034–5040 (2007).
   PubMed Web of Science ®Google Scholar
• Heinrich MC, McArthur GA, Demetri GD et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J. Clin. Oncol. 24(7), 1195–1203 (2006).
   PubMed Web of Science ®Google Scholar
• Chugh R, Wathen JK, Patel SR et al.; Sarcoma Alliance for Research Through Collaboration (SARC). Efficacy of imatinib in aggressive fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research Through Collaboration (SARC) trial. Clin. Cancer Res. 16(19), 4884–4891 (2010).
   PubMed Web of Science ®Google Scholar
• Gounder MM, Lefkowitz RA, Keohan ML et al. Activity of sorafenib against desmoid tumor/deep fibromatosis. Clin. Cancer Res. 17(12), 4082–4090 (2011).
   PubMed Web of Science ®Google Scholar
• Skubitz KM, Manivel JC, Clohisy DR, Frolich JW. Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors. Cancer Chemother. Pharmacol. 64(3), 635–640 (2009).
   PubMed Web of Science ®Google Scholar
• Mignemi NA, Itani DM, Fasig JH et al. Signal transduction pathway analysis in desmoid-type fibromatosis: Transforming growth factor-β, COX2 and sex steroid receptors. Cancer Sci. 103(12), 2173–2180 (2012).
   PubMed Web of Science ®Google Scholar
• Kong Y, Poon R, Nadesan P et al. Matrix metalloproteinase activity modulates tumor size, cell motility, and cell invasiveness in murine aggressive fibromatosis. Cancer Res. 64(16), 5795–5803 (2004).
   PubMed Web of Science ®Google Scholar
• Matono H, Tamiya S, Yokoyama R et al. Abnormalities of the Wnt/β-catenin signalling pathway induce tumour progression in sporadic desmoid tumours: correlation between β-catenin widespread nuclear expression and VEGF overexpression. Histopathology 59(3), 368–375 (2011).
   PubMed Web of Science ®Google Scholar
• Takemaru KI, Ohmitsu M, Li FQ. An oncogenic hub: beta-catenin as a molecular target for cancer therapeutics. Handb. Exp. Pharmacol. 186, 261–284 (2008).
   Google Scholar
• Kotiligam D, Lazar AJ, Pollock RE, Lev D. Desmoid tumor: a disease opportune for molecular insights. Histol. Histopathol. 23(1), 117–126 (2008).
   PubMed Web of Science ®Google Scholar
• Buitendijk S, van de Ven CP, Dumans TG et al. Pediatric aggressive fibromatosis: a retrospective analysis of 13 patients and review of literature. Cancer 104(5), 1090–1099 (2005).
   PubMed Web of Science ®Google Scholar
• Skapek SX, Ferguson WS, Granowetter L et al.; Pediatric Oncology Group. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. J. Clin. Oncol. 25(5), 501–506 (2007).
   PubMed Web of Science ®Google Scholar
• Oudot C, Orbach D, Minard-Colin V et al. Desmoid fibromatosis in pediatric patients: management based on a retrospective analysis of 59 patients and a review of the literature. Sarcoma 2012, 475202 (2012).
   PubMedGoogle Scholar
• Papagelopoulos PJ, Mavrogenis AF, Mitsiokapa EA, Papaparaskeva KT, Galanis EC, Soucacos PN. Current trends in the management of extra-abdominal desmoid tumours. World J. Surg. Oncol. 4, 21 (2006).
   PubMedGoogle Scholar
• Skene AI, Barr L, A’Hern RP, Fisher C, Meirion Thomas J. Multimodality treatment in the control of deep musculoaponeurotic fibromatosis. Br. J. Surg. 85(5), 655–658 (1998).
   PubMed Web of Science ®Google Scholar
• Smith AJ, Lewis JJ, Merchant NB, Leung DH, Woodruff JM, Brennan MF. Surgical management of intra-abdominal desmoid tumours. Br. J. Surg. 87(5), 608–613 (2000).
   PubMed Web of Science ®Google Scholar
• Gronchi A, Casali PG, Mariani L et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J. Clin. Oncol. 21(7), 1390–1397 (2003).
   PubMed Web of Science ®Google Scholar
• Ballo MT, Zagars GK, Pollack A, Pisters PW, Pollack RA. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J. Clin. Oncol. 17(1), 158–167 (1999).
   PubMed Web of Science ®Google Scholar
• Guadagnolo BA, Zagars GK, Ballo MT. Long-term outcomes for desmoid tumors treated with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 71(2), 441–447 (2008).
   PubMed Web of Science ®Google Scholar
• Azzarelli A, Gronchi A, Bertulli R et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer 92(5), 1259–1264 (2001).
   PubMed Web of Science ®Google Scholar
• Bonvalot S, Eldweny H, Haddad V et al. Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. Eur. J. Surg. Oncol. 34(4), 462–468 (2008).
   PubMed Web of Science ®Google Scholar
• Fiore M, Rimareix F, Mariani L et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann. Surg. Oncol. 16(9), 2587–2593 (2009).
   PubMed Web of Science ®Google Scholar
• Salas S, Dufresne A, Bui B et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J. Clin. Oncol. 29(26), 3553–3558 (2011).
   PubMed Web of Science ®Google Scholar
• Mezhir JJ. The desmoid tumor: still an enigma. J. Surg. Res. 173(1), 46–48 (2012).
   PubMed Web of Science ®Google Scholar
• Lev D, Kotilingam D, Wei C et al. Optimizing treatment of desmoid tumors. J. Clin. Oncol. 25(13), 1785–1791 (2007).
   PubMed Web of Science ®Google Scholar
• Lazar AJ, Hajibashi S, Lev D. Desmoid tumor: from surgical extirpation to molecular dissection. Curr. Opin. Oncol. 21(4), 352–359 (2009).
   PubMed Web of Science ®Google Scholar
• Barbier O, Anract P, Pluot E et al. Primary or recurring extra-abdominal desmoid fibromatosis: assessment of treatment by observation only. Orthop. Traumatol. Surg. Res. 96(8), 884–889 (2010).
   PubMed Web of Science ®Google Scholar
• Janinis J, Patriki M, Vini L, Aravantinos G, Whelan JS. The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann. Oncol. 14(2), 181–190 (2003).
   PubMed Web of Science ®Google Scholar
• Garbay D, Le Cesne A, Penel N et al. Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann. Oncol. 23(1), 182–186 (2012).
   PubMed Web of Science ®Google Scholar
• Reich S, Overberg-Schmidt US, Bührer C, Henze G. Low-dose chemotherapy with vinblastine and methotrexate in childhood desmoid tumors. J. Clin. Oncol. 17(3), 1086 (1999).
   PubMed Web of Science ®Google Scholar
• Lackner H, Urban C, Benesch M et al. Multimodal treatment of children with unresectable or recurrent desmoid tumors: an 11-year longitudinal observational study. J. Pediatr. Hematol. Oncol. 26(8), 518–522 (2004).
   PubMed Web of Science ®Google Scholar
• Constantinidou A, Jones RL, Scurr M, Al-Muderis O, Judson I. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur. J. Cancer 45(17), 2930–2934 (2009).
   PubMed Web of Science ®Google Scholar
• Meazza C, Casanova M, Trecate G, Ferrari A. Objective response to hydroxyurea in a patient with heavily pre-treated aggressive fibromatosis. Pediatr. Blood Cancer 55(3), 587–588 (2010).
   PubMed Web of Science ®Google Scholar
• Bisogno G, Tagarelli A, Stramare R, Beltrame V, Carli M. Hydroxyurea treatment can avoid the need for aggressive surgery in pediatric fibromatosis. J. Pediatr. Hematol. Oncol. (2012).
   Google Scholar
• Bocale D, Rotelli MT, Cavallini A, Altomare DF. Anti-oestrogen therapy in the treatment of desmoid tumours: a systematic review. Colorectal Dis. 13(12), e388–e395 (2011).
   PubMed Web of Science ®Google Scholar
• Kinzbrunner B, Ritter S, Domingo J, Rosenthal CJ. Remission of rapidly growing desmoid tumors after tamoxifen therapy. Cancer 52(12), 2201–2204 (1983).
   PubMed Web of Science ®Google Scholar
• Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 100(3), 612–620 (2004).
   PubMed Web of Science ®Google Scholar
• Altomare DF, Rotelli MT, Rinaldi M et al. Potential role of the steroid receptor pattern in the response of inoperable intra-abdominal desmoid to toremifene after failure of tamoxifen therapy. Int. J. Colorectal Dis. 25(6), 787–789 (2010).
   PubMed Web of Science ®Google Scholar
• Merchant TE, Nguyen D, Walter AW, Pappo AS, Kun LE, Rao BN. Long-term results with radiation therapy for pediatric desmoid tumors. Int. J. Radiat. Oncol. Biol. Phys. 47(5), 1267–1271 (2000).
   PubMed Web of Science ®Google Scholar
• Rutenberg MS, Indelicato DJ, Knapik JA et al. External-beam radiotherapy for pediatric and young adult desmoid tumors. Pediatr. Blood Cancer 57(3), 435–442 (2011).
   PubMed Web of Science ®Google Scholar
• Chung EB, Enzinger FM. Infantile fibrosarcoma. Cancer 38(2), 729–739 (1976).
   PubMed Web of Science ®Google Scholar
• Coffin CM, Jaszcz W, O’Shea PA, Dehner LP. So-called congenital-infantile fibrosarcoma: does it exist and what is it? Pediatr. Pathol. 14(1), 133–150 (1994).
   PubMed Web of Science ®Google Scholar
• Ries LAG, Smith MA, Gurney JG et al. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975–1995. National Cancer Institute, MD, USA (1999)
   Google Scholar
• Ferrari A, Alaggio R, Ferrari S. Rare mesenchymal tumors. In: Rare Tumors in Children and Adolescents. Schneider DT, Brecht IB, Olson TA, Ferrari A (Eds). Springer, Berlin, Germany, 485–517 (2012).
   Google Scholar
• Knezevich SR, Garnett MJ, Pysher TJ et al. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res. 58, 5046–5048 (1998).
   PubMed Web of Science ®Google Scholar
• Bourgeois JM, Knezevich SR, Mathers JA, Sorensen PH. Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. Am. J. Surg. Pathol. 24(7), 937–946 (2000).
   PubMed Web of Science ®Google Scholar
• Dal Cin P, Brock P, Casteels-Van Daele M, De Wever I, Van Damme B, Van den Berghe H. Cytogenetic characterization of congenital or infantile fibrosarcoma. Eur. J. Pediatr. 150(8), 579–581 (1991).
   PubMed Web of Science ®Google Scholar
• Gadd S, Beezhold P, Jennings L et al. Mediators of receptor tyrosine kinase activation in infantile fibrosarcoma: a Children’s Oncology Group study. J. Pathol. 228(1), 119–130 (2012).
   PubMed Web of Science ®Google Scholar
• Alaggio R, Ninfo V, Rosolen A, Coffin CM. Primitive myxoid mesenchymal tumor of infancy: a clinicopathologic report of 6 cases. Am. J. Surg. Pathol. 30(3), 388–394 (2006).
   PubMed Web of Science ®Google Scholar
• Ferrari A, Orbach D, Sultan I, Casanova M, Bisogno G. Neonatal soft tissue sarcomas. Semin. Fetal Neonatal Med. 17(4), 231–238 (2012).
   PubMed Web of Science ®Google Scholar
• Steelman C, Katzenstein H, Parham D et al. Unusual presentation of congenital infantile fibrosarcoma in seven infants with molecular-genetic analysis. Fetal Pediatr. Pathol. 30(5), 329–337 (2011).
   PubMed Web of Science ®Google Scholar
• Brisse HJ, Orbach D, Klijanienko J. Soft tissue tumours: imaging strategy. Pediatr. Radiol. 40(6), 1019–1028 (2010).
   PubMed Web of Science ®Google Scholar
• Yan AC, Chamlin SL, Liang MG et al. Congenital infantile fibrosarcoma: a masquerader of ulcerated hemangioma. Pediatr. Dermatol. 23(4), 330–334 (2006).
   PubMed Web of Science ®Google Scholar
• Orbach D, Rey A, Cecchetto G et al. Infantile fibrosarcoma: management based on the European experience. J. Clin. Oncol. 28(2), 318–323 (2010).
   PubMed Web of Science ®Google Scholar
• Ferrari A, Casanova M. New concepts for the treatment of pediatric nonrhabdomyosarcoma soft tissue sarcomas. Expert Rev. Anticancer Ther. 5(2), 307–318 (2005).
   PubMed Web of Science ®Google Scholar
• Coffin CM, Watterson J, Priest JR, Dehner LP. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am. J. Surg. Pathol. 19(8), 859–872 (1995).
   PubMed Web of Science ®Google Scholar
• Coffin CM, Humphrey PA, Dehner LP. Extrapulmonary inflammatory myofibroblastic tumor: a clinical and pathological survey. Semin. Diagn. Pathol. 15(2), 85–101 (1998).
   PubMed Web of Science ®Google Scholar
• Mergan F, Jaubert F, Sauvat F et al. Inflammatory myofibroblastic tumor in children: clinical review with anaplastic lymphoma kinase, Epstein–Barr virus, and human herpesvirus 8 detection analysis. J. Pediatr. Surg. 40(10), 1581–1586 (2005).
   PubMed Web of Science ®Google Scholar
• Alaggio R, Cecchetto G, Bisogno G et al. Inflammatory myofibroblastic tumors in childhood: a report from the Italian Cooperative Group studies. Cancer 116(1), 216–226 (2010).
   PubMed Web of Science ®Google Scholar
• Treissman SP, Gillis DA, Lee CL, Giacomantonio M, Resch L. Omental-mesenteric inflammatory pseudotumor. Cytogenetic demonstration of genetic changes and monoclonality in one tumor. Cancer 73(5), 1433–1437 (1994).
   PubMed Web of Science ®Google Scholar
• Chen ST, Lee JC. An inflammatory myofibroblastic tumor in liver with ALK and RANBP2 gene rearrangement: combination of distinct morphologic, immunohistochemical, and genetic features. Hum. Pathol. 39(12), 1854–1858 (2008).
   PubMed Web of Science ®Google Scholar
• Bridge JA, Kanamori M, Ma Z et al. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am. J. Pathol. 159(2), 411–415 (2001).
   PubMed Web of Science ®Google Scholar
• Cook JR, Dehner LP, Collins MH et al. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am. J. Surg. Pathol. 25(11), 1364–1371 (2001).
   PubMed Web of Science ®Google Scholar
• Coffin CM, Patel A, Perkins S, Elenitoba-Johnson KS, Perlman E, Griffin CA. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod. Pathol. 14(6), 569–576 (2001).
   PubMed Web of Science ®Google Scholar
• Chun YS, Wang L, Nascimento AG, Moir CR, Rodeberg DA. Pediatric inflammatory myofibroblastic tumor: anaplastic lymphoma kinase (ALK) expression and prognosis. Pediatr. Blood Cancer 45(6), 796–801 (2005).
   PubMed Web of Science ®Google Scholar
• Meis JM, Enzinger FM. Inflammatory fibrosarcoma of the mesentery and retroperitoneum. A tumor closely simulating inflammatory pseudotumor. Am. J. Surg. Pathol. 15(12), 1146–1156 (1991).
   PubMed Web of Science ®Google Scholar
• Hussong JW, Brown M, Perkins SL, Dehner LP, Coffin CM. Comparison of DNA ploidy, histologic, and immunohistochemical findings with clinical outcome in inflammatory myofibroblastic tumors. Mod. Pathol. 12(3), 279–286 (1999).
   PubMed Web of Science ®Google Scholar
• Coffin CM, Hornick JL, Fletcher CD. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am. J. Surg. Pathol. 31(4), 509–520 (2007).
   PubMed Web of Science ®Google Scholar
• Dishop MK, Warner BW, Dehner LP et al. Successful treatment of inflammatory myofibroblastic tumor with malignant transformation by surgical resection and chemotherapy. J. Pediatr. Hematol. Oncol. 25(2), 153–158 (2003).
   PubMed Web of Science ®Google Scholar
• Favini F, Resti AG, Collini P et al. Inflammatory myofibroblastic tumor of the conjunctiva: response to chemotherapy with low-dose methotrexate and vinorelbine. Pediatr. Blood Cancer 54(3), 483–485 (2010).
   PubMed Web of Science ®Google Scholar
• Applebaum H, Kieran MW, Cripe TP et al. The rationale for nonsteroidal anti-inflammatory drug therapy for inflammatory myofibroblastic tumors: a Children’s Oncology Group Study. J. Pediatr. Surg. 40(6), 999–1003; discussion 1003 (2005).
   PubMed Web of Science ®Google Scholar
• Berger A, Kim C, Hagstrom N, Ferrer F. Successful preoperative treatment of pediatric bladder inflammatory myofibroblastic tumor with anti-inflammatory therapy. Urology 70(2), 372.e13–372.e15 (2007).
   Google Scholar
• Lee MH, Lee HB, Lee YC et al. Bilateral multiple inflammatory myofibroblastic tumors of the lung successfully treated with corticosteroids. Lung 189(5), 433–435 (2011).
   PubMed Web of Science ®Google Scholar
• Butrynski JE, D’Adamo DR, Hornick JL et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N. Engl. J. Med. 363(18), 1727–1733 (2010).
   PubMed Web of Science ®Google Scholar
• Olson TA, Schneider DT, Brecht IB, Ferrari A. Rare tumors: a different perspective on oncology. In: Rare Tumors in Children and Adolescents. Schneider DT, Brecht IB, Olson TA, Ferrari A (Eds). Springer, Berlin, UK, 3–15 (2012).
   Google Scholar